Blue Trust Inc. Buys 1,066 Shares of Johnson & Johnson $JNJ

Blue Trust Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,941 shares of the company’s stock after purchasing an additional 1,066 shares during the period. Blue Trust Inc.’s holdings in Johnson & Johnson were worth $10,225,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Horizon Bancorp Inc. IN grew its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after buying an additional 64 shares during the last quarter. Global Strategic Investment Solutions LLC raised its position in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares during the period. JSF Financial LLC raised its position in Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after acquiring an additional 65 shares during the period. Elios Financial Group Inc. raised its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares during the period. Finally, Atlantic Family Wealth LLC raised its position in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after purchasing an additional 67 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.66 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a fifty day moving average of $178.48 and a two-hundred day moving average of $163.78. The stock has a market capitalization of $459.16 billion, a PE ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion during the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on JNJ shares. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a research note on Friday, October 3rd. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America boosted their price objective on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, HSBC boosted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.